SEC Stock Data Quick Answer Zenas BioPharma, Inc. reported R&D Expense of $168.06 million for fiscal year 2025. Zenas BioPharma, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $168.06M +20.8% 2024 $139.14M +131.8% 2023 $60.03M — Quarterly R&D Expense Quarter Ending R&D Expense YoY QoQ September 30, 2025 $34.40M +2.6% -20.0% June 30, … Read more
Quick Answer Zenas BioPharma, Inc. reported Stockholders Equity of $242.14 million for fiscal year 2025. Zenas BioPharma, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $242.14M -22.5% 2024 $312.46M +238.4% 2023 -$225.72M -17.4% 2022 -$192.29M — Quarterly Stockholders Equity Quarter Ending Stockholders Equity YoY QoQ September 30, 2025 $196.43M -45.4% … Read more
Quick Answer Zenas BioPharma, Inc. reported Long-Term Debt of $78.64 million for fiscal year 2025. Zenas BioPharma, Inc. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2025 $78.64M — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY QoQ September 30, 2025 $72.99M — — The most recent figure is from Zenas BioPharma, … Read more
Quick Answer Zenas BioPharma, Inc. reported Cash and Equivalents of $110.64 million for fiscal year 2025. Zenas BioPharma, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $110.64M -65.4% 2024 $319.74M +462.4% 2023 $56.86M — Quarterly Cash and Equivalents Quarter Ending Cash and Equivalents YoY QoQ September 30, 2025 … Read more
Quick Answer Zenas BioPharma, Inc. reported Total Assets of $383.64 million for fiscal year 2025. Zenas BioPharma, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $383.64M +3.7% 2024 $369.97M +442.6% 2023 $68.18M — Quarterly Total Assets Quarter Ending Total Assets YoY QoQ September 30, 2025 $322.02M -20.2% +9.9% June 30, … Read more
Quick Answer Zenas BioPharma, Inc. reported Diluted EPS of $8.44 per share (loss) for fiscal year 2025. Zenas BioPharma, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$8.44 +29.0% 2024 -$11.89 +51.0% 2023 -$24.25 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ September 30, 2025 -$1.22 +75.7% +2.4% … Read more
Quick Answer Zenas BioPharma, Inc. reported Net Income of -$377.74 million for fiscal year 2025. Zenas BioPharma, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$377.74M -140.6% 2024 -$156.99M -322.9% 2023 -$37.12M — Quarterly Net Income Quarter Ending Net Income YoY QoQ September 30, 2025 -$51.50M -33.4% +1.4% June 30, … Read more
Quick Answer Zenas BioPharma, Inc. reported Revenue (ASC 606) of $10.00 million for fiscal year 2025. Zenas BioPharma, Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $10.00M +100.0% 2024 $5.00M -90.0% 2023 $50.00M — Quarterly Revenue (ASC 606) Quarter Ending Revenue (ASC 606) YoY QoQ March 31, 2025 … Read more
Quick Answer Zenas BioPharma, Inc. reported Total Revenue of $10.00 million for fiscal year 2025. Zenas BioPharma, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $10.00M +100.0% 2024 $5.00M -90.0% 2023 $50.00M — Quarterly Total Revenue Quarter Ending Total Revenue YoY QoQ September 30, 2025 $0.00 — — June 30, … Read more
Quick Answer Zenas BioPharma, Inc. reported Total Revenue of $10.00 million for fiscal year 2025. Zenas BioPharma, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 Total Revenue $10.00M+100.0% $5.00M-90.0% $50.00M — Revenue (ASC 606) $10.00M+100.0% $5.00M-90.0% $50.00M — Net Income -$377.74M-140.6% -$156.99M-322.9% -$37.12M — Diluted EPS -$8.44+29.0% -$11.89+51.0% -$24.25 — Total Assets … Read more